Clorox (CLX) Cash & Equivalents (2009 - 2026)

Clorox's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 425.22% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 425.22% increase from a year earlier, with the FY2025 full-year figure at $167.0 million, down 17.33% from the prior year.
• Cash & Equivalents improved to $1.2 billion in Q1 2026 per CLX's latest filing, from $227.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.2 billion in Q1 2026 and bottomed at $166.0 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $241.0 million (2022), against an average of $312.6 million.
• Across the five-year window, Cash & Equivalents slumped 51.02% in 2022 and soared 425.22% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $168.0 million in 2022, then soared by 111.31% to $355.0 million in 2023, then decreased by 18.31% to $290.0 million in 2024, then slipped by 21.72% to $227.0 million in 2025, then jumped by 422.91% to $1.2 billion in 2026.
• Per Business Quant, the three latest CLX Cash & Equivalents figures stand at $1.2 billion (Q1 2026), $227.0 million (Q4 2025), and $166.0 million (Q3 2025).